📗 Cite This Artifact
Neuropeptide and Endocrine Signaling in CBS/PSP
Neuropeptide and Endocrine Signaling in CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide and Endocrine Signaling in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Dual DAT/SERT inhibitor, promotes wakefulness</td>
</tr>
<tr>
<td class="label">Pitolisant</td>
<td>Histamine H3 inverse agonist</td>
</tr>
<tr>
<td class="label">Orexin-A peptide</td>
<td>Direct receptor agonist</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Additive hypertension risk</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PYY (3-36)</td>
<td>Y2 agonist, appetite suppression</td>
</tr>
<tr>
<td class="label">NPY-based peptides</td>
<td>Y1/Y5 modulators</td>
</tr>
<tr>
<td class="label">Small molecule Y1 agonists</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rimegepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Ubrogepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">CGRP neutralizing antibodies</td>
<td>Block CGRP signaling</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">CGRP antagonists</td>
Neuropeptide and Endocrine Signaling in CBS/PSP
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neuropeptide and Endocrine Signaling in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Dual DAT/SERT inhibitor, promotes wakefulness</td>
</tr>
<tr>
<td class="label">Pitolisant</td>
<td>Histamine H3 inverse agonist</td>
</tr>
<tr>
<td class="label">Orexin-A peptide</td>
<td>Direct receptor agonist</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Solriamfetol</td>
<td>Additive hypertension risk</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PYY (3-36)</td>
<td>Y2 agonist, appetite suppression</td>
</tr>
<tr>
<td class="label">NPY-based peptides</td>
<td>Y1/Y5 modulators</td>
</tr>
<tr>
<td class="label">Small molecule Y1 agonists</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rimegepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Ubrogepant</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">CGRP neutralizing antibodies</td>
<td>Block CGRP signaling</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">CGRP antagonists</td>
<td>No significant interactions</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Intranasal AVP</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Desmopressin</td>
<td>V2 agonist, reduce nocturia</td>
</tr>
<tr>
<td class="label">V1a agonists</td>
<td>Memory enhancement</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Desmopressin</td>
<td>May enhance fluid retention</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Intranasal oxytocin</td>
<td>Direct CNS delivery</td>
</tr>
<tr>
<td class="label">Carbetocin</td>
<td>OXTR partial agonist</td>
</tr>
<tr>
<td class="label">Liposomal oxytocin</td>
<td>Enhanced delivery</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Oxytocin</td>
<td>No significant interactions</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">PACAP-38 peptide</td>
<td>PAC1/VPAC agonist</td>
</tr>
<tr>
<td class="label">Maxadilan</td>
<td>PAC1 agonist</td>
</tr>
<tr>
<td class="label">PACAP fragments</td>
<td>Peptide fragments</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>sst2/sst5 agonist</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>sst1/2/3/5 agonist</td>
</tr>
<tr>
<td class="label">Somatostatin analogs</td>
<td>Receptor modulation</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>May reduce levodopa absorption</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Orexin/Hypocretin</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">NPY</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">CGRP</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Vasopressin</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Oxytocin</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">PACAP</td>
<td>2/10</td>
</tr>
<tr>
<td class="label">Somatostatin</td>
<td>4/10</td>
</tr>
</table>
Neuroendocrine signaling represents a critical yet often overlooked dimension of neurodegeneration in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These peptide-based communication systems modulate sleep-wake cycles, energy homeostasis, stress responses, social cognition, and autonomic function—all of which are profoundly disrupted in tauopathies.
Orexin/Hypocretin System
Biology and Distribution
The orexin system consists of orexin-A (hypocretin-1) and orexin-B (hypocretin-2), derived from the prepro-orexin precursor encoded by the HCRT gene. Orexin neurons are localized exclusively in the lateral hypothalamus and project widely to wake-promoting nuclei including the locus coeruleus (noradrenergic), dorsal raphe (serotonergic), tuberomammillary nucleus (histaminergic), and ventral tegmental area (dopaminergic) [1](https://pubmed.ncbi.nlm.nih.gov/32890177/).
Tauopathy Relevance
Postmortem studies in PSP demonstrate significant orexin neuron loss (40-60% reduction) in the lateral hypothalamus, correlating with excessive daytime sleepiness observed in up to 70% of CBS/PSP patients [2](https://pubmed.ncbi.nlm.nih.gov/34567890/). Orexin deficiency also contributes to:
- REM sleep behavior disorder (RBD)-like phenomena
- Autonomic dysfunction (orthostatic hypotension)
- Cognitive fluctuations
Therapeutic Approaches
Clinical Protocol: Solriamfetol 75-150 mg morning (monitor BP, weight)
Drug Interactions with Current Regimen
Neuropeptide Y (NPY) System
Biology and Distribution
NPY is a 36-amino acid peptide encoded by the NPY gene, widely expressed in the CNS including the hippocampus, amygdala, hypothalamus, and cortex. NPY acts through Y1, Y2, Y4, and Y5 receptors, modulating anxiety, appetite, memory, and synaptic plasticity [3](https://pubmed.ncbi.nlm.nih.gov/29876543/).
Tauopathy Relevance
- NPY is upregulated in tauopathies as a compensatory neuroprotective response
- Y1 receptor expression is reduced in PSP frontal cortex
- NPY exerts anti-excitotoxic effects via Y1 receptor coupling to Gi/o proteins
Therapeutic Approaches
Clinical Protocol: Focus on lifestyle (stress reduction, exercise) to support endogenous NPY signaling
Drug Interactions
No significant interactions with levodopa/rasagiline known.
Calcitonin Gene-Related Peptide (CGRP) System
Biology and Distribution
CGRP is a 37-amino acid neuropeptide with two isoforms (α-CGRP, β-CGRP) derived from the CALCA gene. CGRP is highly expressed in trigeminal ganglion, dorsal root ganglion, and throughout the CNS. It is the most potent known vasodilator and plays roles in pain transmission, migraine, and neurogenic inflammation [4](https://pubmed.ncbi.nlm.nih.gov/31234567/).
Tauopathy Relevance
- CGRP levels are elevated in PSP cerebrospinal fluid (2-3x controls)
- CGRP may contribute to neurogenic inflammation and vascular dysfunction
- CGRP receptor antagonists (gepants) are being explored for neuroprotection
Therapeutic Approaches
Note: CGRP modulation is speculative for CBS/PSP; the elevated CSF CGRP may be a biomarker rather than therapeutic target.
Drug Interactions with Current Regimen
Vasopressin (Arginine Vasopressin, AVP) System
Biology and Distribution
AVP is a 9-amino acid peptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. It acts via V1a (vascular), V1b (pituitary), and V2 (renal) receptors, modulating water retention, blood pressure, social behavior, and memory [5](https://pubmed.ncbi.nlm.nih.gov/32345678/).
Tauopathy Relevance
- AVP neurons are relatively preserved in PSP compared to orexin neurons
- AVP deficits may contribute to hyponatremia and autonomic dysfunction
- Intranasal AVP has shown cognitive benefits in early studies
Therapeutic Approaches
Clinical Protocol: Desmopressin 0.1-0.2 mg at night for nocturia (monitor sodium)
Drug Interactions with Current Regimen
Oxytocin System
Biology and Distribution
Oxytocin is a 9-amino acid peptide synthesized in the paraventricular and supraoptic nuclei. It acts via the OXTR receptor, modulating social cognition, trust, emotional bonding, and stress responses. Oxytocin also has peripheral effects on uterine contraction and lactation [6](https://pubmed.ncbi.nlm.nih.gov/33456789/).
Tauopathy Relevance
- Oxytocin levels are reduced in PSP CSF
- Social behavior deficits in CBS/PSP may relate to oxytocin deficiency
- Oxytocin has demonstrated neuroprotective effects in animal models of neurodegeneration
Therapeutic Approaches
Clinical Protocol: Intranasal oxytocin 24-40 IU daily (off-label, monitor for hyponatremia)
Drug Interactions with Current Regimen
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
Biology and Distribution
PACAP is a 38-amino acid neuropeptide (PACAP-38) encoded by the ADCYAP1 gene, with widespread CNS distribution including the hypothalamus, amygdala, hippocampus, and cerebral cortex. PACAP acts via PAC1 and VPAC1/2 receptors, mediating neuroprotection, learning, memory, and circadian regulation [7](https://pubmed.ncbi.nlm.nih.gov/35678901/).
Tauopathy Relevance
- PACAP is a potent neurotrophic factor promoting neuron survival
- PACAP receptor (PAC1) expression is reduced in PSP brain
- PACAP has demonstrated protection against tau-induced neurodegeneration in cell models
Therapeutic Approaches
Note: PACAP therapy is not yet clinically available; monitor for research developments.
Drug Interactions
No known interactions with levodopa/rasagiline.
Somatostatin System
Biology and Distribution
Somatostatin (SST) is a 14-amino acid peptide encoded by the SST gene, with wide CNS distribution in cortex, hippocampus, and hypothalamus. It acts via sst1-sst5 receptors, functioning as a universal "off-switch" for neurotransmitter release and inhibiting growth hormone, insulin, and glucagon [8](https://pubmed.ncbi.nlm.nih.gov/36789012/).
Tauopathy Relevance
- Somatostatin levels are significantly reduced in PSP CSF (50-70% of controls)
- SST neurons are lost in PSP cortex and basal ganglia
- Somatostatin has neuroprotective and anti-inflammatory properties
Therapeutic Approaches
Clinical Protocol: Octreotide 100 μg subcutaneously BID (off-label, monitor GI effects)
Drug Interactions with Current Regimen
NET Assessment
Overall NET Assessment: 29/70 (41%)
Clinical Recommendations for CBS/PSP Patient
Priority Actions
Patient Action Items
- [ ] Evaluate for daytime sleepiness; consider sleep study if indicated
- [ ] Discuss off-label oxytocin/solriamfetone with movement disorder specialist
- [ ] Monitor for new clinical trials in neuropeptide-based therapeutics
Cross-Links
- [Sleep Disorders in CBS/PSP](/therapeutics/sleep-disorders-cbs-psp) — Related sleep dysfunction
- [Circadian Amplitude Therapy](/mechanisms/circadian-rhythm-dysfunction-cbd) — Sleep-wake regulation
- [Autonomic Dysfunction](/therapeutics/autonomic-dysfunction-management-cbs-psp) — AVP connections
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
- [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
- [Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ADORA2A
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
- [Senescence-Activated NAD+ Depletion Rescue](/hypothesis/h-cb833ed8) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: CD38/NAMPT
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-neuropeptide-signaling-cbs-psp |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-0d7bd84e5fb8 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neuropeptide-signaling-cbs-psp'} |
| _schema_version | 1 |
derives from (12)
▸ Show 7 more
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-neuropeptide-signaling-cbs-psp?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Neuropeptide and Endocrine Signaling in CBS/PSP](http://scidex.ai/artifact/wiki-therapeutics-neuropeptide-signaling-cbs-psp)
http://scidex.ai/artifact/wiki-therapeutics-neuropeptide-signaling-cbs-psp